Biotech Values

[DewDiligence]

GILD submits MAA for TMC278+Truvada combination pill:

http://finance.yahoo.com/news/Gilead-Sciences-Submits-bw-3701001340.html?x=0&.v=1

An MAA is the EU’s version of a new drug application. GILD’s MAA submission is a few weeks early relative to GILD’s prior guidance for 4Q10 submissions to both the EMA and FDA; GILD’s NDA submission for TMC278+Truvada is awaiting the FDA’s acceptance for review of JNJ’s separate NDA for standalone TMC278, which was submitted on 7/26/10 (#msg-52656751).

The TMC278 + Truvada combo pill has been referred to as Btripla by some investors and analysts because it is intended to compete with the blockbuster, Atripla (#msg-54039347).